Market Update (NASDAQ:AMGN): Amgen’s cancer immunotherapy fails to impress FDA staff reviewers

[Reuters] – U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc’s skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results . . . → Read More: Market Update (NASDAQ:AMGN): Amgen’s cancer immunotherapy fails to impress FDA staff reviewers Similar Articles: Market Update (NASDAQ:AMGN): Amgen’s cancer immunotherapy fails to impress FDA staff reviewers Market Update (NASDAQ:AMGN): Amgen’s cancer immunotherapy fails to impress FDA staff reviewers Market Update (NASDAQ:AMGN): Amgen’s cancer immunotherapy fails to impress FDA staff reviewers